Original Paper

NPM1 and FLT3-(ITD) Gene mutations and laboratory findings in patients with acute myeloid leukemia in Northwest of Iran

Sanaat Z (M.D)¹, Shams K (Ph.D)², Nejati B (M.D)², Movasghpour AK (Ph.D)² Imani V (M.D)³, Moghadaszadeh M (M.D)*⁴

¹Associate Professor, Hematology Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
²Assistant Professor, Hematology Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
³Resident in Pediatrics, Tabriz University of Medical Sciences, Tabriz, Iran.
⁴Internist, Department of Internal Medicine, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.

Abstract

Background and Objective: The acute myeloid leukemia (AML) is a malignant disease with an accumulation of the abnormal and undifferentiated blastic myeloid cell in the bone marrow, leading to abnormal hematopoiesis. This study was done to determine the NPM1 and FLT3-(ITD) mutations and laboratory findings in patients with acute myeloid leukemia.

Methods: This descriptive-analytic study was carried out on 40 (24 males, 16 females) patients with newly acute myeloid leukemia in Northwest of Iran. The mutation of NPM1 and FLT3-ITD were evaluated using PCR method in 25 patients. In all patients, the flowcytometry findings in the bone marrow, leucocytosis and the LDH levels were evaluated prior to the chemotherapy.

Results: The mutation of FLT3-ITD and NPM1 genes was detected in 15 (60%) and 9 (36%) of patients, respectively. FLT3-NPM1+ mutation was seen in 4 (16%) patients. Leukocytosis, LDH level and AML in different classes did no show any significant difference between FLT3-NPM1+ and other gene mutations.

Conclusion: The mutation of FLT3-ITD gene was nearly twice than NPM1 in acute myeloid leukemia.

Keywords: Acute myeloid leukemia, NPM1 gene, FLT3-ITD gene, Leukocytosis

* Corresponding Author: Moghadaszadeh M (M.D), E-mail: m moghadaszadeh@hotmail.com

Received 29 Jun 2013 Revised 4 May 2014 Accepted 17 May 2014